During the last session, Hepion Pharmaceuticals Inc (NASDAQ:HEPA)’s traded shares were 22.52 million, with the beta value of the company hitting 1.58. The 52-week high for the HEPA share is $3.49, that puts it down -1645.0 from that peak though still a striking 40.0% gain since the share price plummeted to a 52-week low of $0.12. The company’s market capitalization is $2.15M, and the average trade volume was 18.91 million shares over the past three months.

Hepion Pharmaceuticals Inc (HEPA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. HEPA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information

Hepion Pharmaceuticals Inc (HEPA) registered a 1.05% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.05% in intraday trading to $0.20, hitting a weekly high. The stock’s 5-day price performance is 24.14%, and it has moved by -57.35% in 30 days. Based on these gigs, the overall price performance for the year is -86.67%.

The consensus price target of analysts on Wall Street is $70, which implies an increase of 99.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $70 and $70 respectively. As a result, HEPA is trading at a discount of -34900.0% off the target high and -34900.0% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 63.67%.

HEPA Dividends

Hepion Pharmaceuticals Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.